Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

FDA Updates Durvalumab NSCLC Label to Include OS Data

Gina Columbus @ginacolumbusonc
Published: Monday, Jul 22, 2019

The FDA has updated the label for durvalumab (Imfinzi) for patients with unresectable, stage III non–small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemoradiation to include overall survival (OS) data from the phase III PACIFIC trial.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication